echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yuan Dong, Ted...The siege surged by 300% injections! Osaikon is here too

    Yuan Dong, Ted...The siege surged by 300% injections! Osaikon is here too

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News, March 25.
    Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
    According to data from Menet.
    com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
     
    Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.
    Secondary hyperparathyroidism.
     
    Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years
    Source: Terminal competition landscape of China's public medical institutions
     
    Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.
    According to data from Menet.
    com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
    Among them, Hengrui Medicine has the largest market share, exceeding 80%.
     
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
    In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
    At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
    Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
     
    Source: Mi Nei Net database
    Medical Network News, March 25.
    Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
    According to data from Menet.
    com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
     
    Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.
    Secondary hyperparathyroidism.
     
    Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years
    Source: Terminal competition landscape of China's public medical institutions
     
      Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.
    According to data from Menet.
    com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
    Among them, Hengrui Medicine has the largest market share, exceeding 80%.
     
      
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
      In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
    At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
    Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
     
      Source: Mi Nei Net database
      Medical Network News, March 25.
    Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
    According to data from Menet.
    com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
     
      Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.
    Secondary hyperparathyroidism.
     
      Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years
      Source: Terminal competition landscape of China's public medical institutions
     
      Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.
    According to data from Menet.
    com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
    Among them, Hengrui Medicine has the largest market share, exceeding 80%.
    Hospital Hospital Hospital Medicine Medicine Medicine
     
      
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
      In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
    At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
    Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
     
      Source: Mi Nei Net database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.